4 recruiting, 1 enrolling by invitation, 1 not yet recruiting. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Recruiting 4, Enrolling by invitation 1, Not yet recruiting 1 |
Follow Crohn Disease (CD): new trials by email Literature Review of Crohn Disease (CD) trials Research Report on Crohn Disease (CD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INSIGHT-IBD Pragmatic Study Mirikizumab, Anti-TNF agents, anti-integrin antibodies - Ulcerative Colitis (UC), Crohn Disease (CD) | Phase 4 | Enrolling by invitation | Specialty Networks Research. | 400 | 2026-08-12 | 2026-10-29 |
| Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter Study Guselkumab - Crohn Disease (CD), Intensification | Phase 4 | Recruiting | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 210 | 2026-06-18 | 2026-06-30 |
| Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease Mirikizumab - IV, Mirikizumab - SC - Crohn Disease (CD) | Phase 4 | Recruiting | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | 75 | 2026-05-11 | 2026-05-26 |
| TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response Upadacitinib, Infliximab Dose Intensification, Adalimumab Dose Intensification - Crohn Disease (CD) | Phase 4 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 312 | 2026-03-01 | 2026-06-09 |
| De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis Ustekinumab 90 mg SC q8w, Ustekinumab 90 mg SC q12w - Crohn Disease (CD), Ulcerative Colitis (UC) | Phase 4 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 115 | 2025-10-08 | 2025-12-26 |
| Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis Mirikizumab - Crohn Disease (CD), Crohns Disease | Phase 4 | Not yet recruiting | Rubix LS | 150 | 2025-07-16 | 2025-07-10 |
Crohn Disease (6) · Colitis, Ulcerative (3)
Digestive System Diseases (6) · Gastroenteritis (6) · Gastrointestinal Diseases (6) · Inflammatory Bowel Diseases (6) · Intestinal Diseases (6) · Colitis (3) · Colonic Diseases (3)
mirikizumab (2) · Adalimumab (1) · Infliximab (1) · Interleukin-12 (1) · Interleukin-23 (1) · Ustekinumab (1) · guselkumab (1) · upadacitinib (1)
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (2) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Rubix LS (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Specialty Networks Research. (1)
France (2) · United States (2) · Canada (1) · China (1)
Casey Chapman, MD (1) · Mathurin Fumery, Investigator (1) · Nicholas Lazarou, MPH, MBA (1)
2025 (2)